Press Releases Year None202320222021202020192018201720162015201420132012201120102009 05/30/23 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June 05/09/23 Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update 05/07/23 Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors 05/03/23 Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023 05/01/23 Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders 04/25/23 Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023 04/13/23 Exelixis Advances Board Refreshment Plan 04/05/23 Exelixis Reiterates Commitment to Shareholder Value Creation 03/20/23 Exelixis Announces $550 Million Share Repurchase Program 03/13/23 Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit 03/02/23 Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer 02/28/23 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March 02/13/23 Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma 02/13/23 Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors 02/07/23 Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update 02/02/23 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February 01/24/23 Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023 01/19/23 Exelixis Announces Update on Patent Litigation with MSN Laboratories 01/08/23 Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023 01/03/23 Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —
